ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2007
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.Journal of neurology · 2024Review
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Observational
- Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2017Review
- B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.CNS drugs · 2016Review
- B cell-derived transforming growth factor-β1 expression limits the induction phase of autoimmune neuroinflammation.Scientific reports · 2016Article
- Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Journal of neurology · 2016Observational
- Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen.Acta neuropathologica · 2016Article
- An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.Therapeutic advances in neurological disorders · 2016Review
- A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.Journal of neurology · 2012Review
- Current options for the treatment of optic neuritis.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- Update on neuromyelitis optica: natural history and management.Eye and brain · 2012Review
- Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.CNS drugs · 2012Review
- Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.Journal of neuroinflammation · 2011Article
- Current and future treatment approaches for neuromyelitis optica.Therapeutic advances in neurological disorders · 2011Article
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.Therapeutic advances in neurological disorders · 2010Article
- Neuromyelitis optica: diagnosis, pathogenesis, and treatment.Current neurology and neuroscience reports · 2008Review
- Immune agents for the treatment of Devic's neuromyelitis optica.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2007Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.
Indexed as
Identifiers
17690854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.